Abeona Therapeutics Inc (NASDAQ:ABEO - Get Free Report) has been assigned an average rating of "Buy" from the five research firms that are presently covering the company, Marketbeat reports. Five research analysts have rated the stock with a buy recommendation. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $19.25.
Several analysts recently commented on the stock. Wall Street Zen downgraded shares of Abeona Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 15th. HC Wainwright raised their price target on Abeona Therapeutics from $15.00 to $20.00 and gave the stock a "buy" rating in a report on Wednesday, April 30th. Alliance Global Partners reaffirmed a "buy" rating on shares of Abeona Therapeutics in a report on Thursday, May 15th. Oppenheimer began coverage on shares of Abeona Therapeutics in a research note on Monday, June 2nd. They issued an "outperform" rating and a $19.00 price objective on the stock. Finally, Stifel Nicolaus dropped their price target on shares of Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating on the stock in a research note on Friday, May 16th.
Check Out Our Latest Analysis on ABEO
Abeona Therapeutics Stock Performance
Shares of ABEO stock traded down $0.08 during mid-day trading on Friday, hitting $6.16. 373,536 shares of the stock were exchanged, compared to its average volume of 643,953. The stock's fifty day simple moving average is $5.69 and its two-hundred day simple moving average is $5.59. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. Abeona Therapeutics has a 12-month low of $3.93 and a 12-month high of $7.32. The stock has a market capitalization of $315.13 million, a price-to-earnings ratio of -2.29 and a beta of 1.54.
Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.11. On average, analysts forecast that Abeona Therapeutics will post -1.16 EPS for the current year.
Insider Buying and Selling
In other Abeona Therapeutics news, CEO Vishwas Seshadri sold 50,676 shares of the business's stock in a transaction on Friday, June 6th. The stock was sold at an average price of $6.76, for a total transaction of $342,569.76. Following the sale, the chief executive officer now directly owns 1,303,761 shares in the company, valued at approximately $8,813,424.36. The trade was a 3.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Joseph Walter Vazzano sold 17,795 shares of the firm's stock in a transaction on Friday, June 6th. The shares were sold at an average price of $6.76, for a total value of $120,294.20. Following the completion of the transaction, the chief financial officer now owns 491,246 shares of the company's stock, valued at approximately $3,320,822.96. This represents a 3.50% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 113,941 shares of company stock valued at $711,341. Corporate insiders own 6.90% of the company's stock.
Institutional Trading of Abeona Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of ABEO. Wellington Management Group LLP purchased a new stake in Abeona Therapeutics in the 4th quarter valued at approximately $520,000. Jane Street Group LLC lifted its position in shares of Abeona Therapeutics by 894.8% in the fourth quarter. Jane Street Group LLC now owns 131,478 shares of the biopharmaceutical company's stock valued at $732,000 after acquiring an additional 118,262 shares in the last quarter. Trexquant Investment LP acquired a new stake in shares of Abeona Therapeutics during the fourth quarter valued at $382,000. Squarepoint Ops LLC purchased a new stake in Abeona Therapeutics during the 4th quarter worth about $67,000. Finally, Northern Trust Corp lifted its holdings in Abeona Therapeutics by 6.6% in the 4th quarter. Northern Trust Corp now owns 184,929 shares of the biopharmaceutical company's stock valued at $1,030,000 after purchasing an additional 11,478 shares in the last quarter. Hedge funds and other institutional investors own 80.56% of the company's stock.
Abeona Therapeutics Company Profile
(
Get Free ReportAbeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
See Also
Before you consider Abeona Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abeona Therapeutics wasn't on the list.
While Abeona Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
